BUZZ-Skye Bioscience rises as it partners with Halozyme on obesity drug

Reuters01-05

BUZZ-<a href="https://laohu8.com/S/SKYE">Skye Bioscience</a> rises as it partners with Halozyme on obesity drug

** Shares of drug developer Skye Bioscience SKYE.O rise 4.76% to $0.92 premarket

** Co says it has signed a global agreement with Halozyme Therapeutics HALO.O to develop and potentially commercialize a new obesity treatment

** SKYE says deal will develop injectable version of nimacimab, an experimental obesity drug

** Nimacimab aims to help with weight loss; study to test combo with GLP-1 drugs already used for obesity - SKYE

** Co plans mid-stage trial of new formulation in mid-2026

** Halozyme to get milestone payments and royalties if drug is approved and launched - SKYE

** As of last close, stock up ~17% over the past year

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601788664?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-05 20:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601788664","market":"us","top_or_hot":-1,"title":"BUZZ-Skye Bioscience rises as it partners with Halozyme on obesity drug","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/SKYE\">Skye Bioscience</a> rises as it partners with Halozyme on obesity drug</title></head><body><p>** Shares of drug developer Skye Bioscience <span>SKYE.O</span> rise 4.76% to $0.92 premarket</p><p>** Co says it has signed a global agreement with Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>HALO.O</span> to develop and potentially commercialize a new obesity treatment</p><p>** SKYE says deal will develop injectable version of nimacimab, an experimental obesity drug</p><p>** Nimacimab aims to help with weight loss; study to test combo with GLP-1 drugs already used for obesity - SKYE</p><p>** Co plans mid-stage trial of new formulation in mid-2026</p><p>** Halozyme to get milestone payments and royalties if drug is approved and launched - SKYE</p><p>** As of last close, stock up ~17% over the past year</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Skye Bioscience rises as it partners with Halozyme on obesity drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Skye Bioscience rises as it partners with Halozyme on obesity drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-05 20:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/SKYE\">Skye Bioscience</a> rises as it partners with Halozyme on obesity drug</title></head><body><p>** Shares of drug developer Skye Bioscience <span>SKYE.O</span> rise 4.76% to $0.92 premarket</p><p>** Co says it has signed a global agreement with Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>HALO.O</span> to develop and potentially commercialize a new obesity treatment</p><p>** SKYE says deal will develop injectable version of nimacimab, an experimental obesity drug</p><p>** Nimacimab aims to help with weight loss; study to test combo with GLP-1 drugs already used for obesity - SKYE</p><p>** Co plans mid-stage trial of new formulation in mid-2026</p><p>** Halozyme to get milestone payments and royalties if drug is approved and launched - SKYE</p><p>** As of last close, stock up ~17% over the past year</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HALO","symbol_name":"奥洛兹美医疗","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nL4N3Y60SD:1","article_id":"2601788664","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601788664","pubTimestamp":1767615228,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Skye Bioscience rises as it partners with Halozyme on obesity drug** Shares of drug developer Skye Bioscience SKYE.O rise 4.76% to $0.92 premarket** Co says it has signed a global agreement with Halozyme Therapeutics HALO.O to develop and potentially commercialize a new obesity treatment** SKYE says deal will develop injectable version of nimacimab, an experimental obesity drug** Nimacimab aims to help with weight loss; study to test combo with GLP-1 drugs already used for obesity - SKYE** Co plans mid-stage trial of new formulation in mid-2026** Halozyme to get milestone payments and royalties if drug is approved and launched - SKYE** As of last close, stock up ~17% over the past year  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HALO":"奥洛兹美医疗","BK4139":"生物科技","SKYE":"Skye Bioscience Inc.","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)"},"translate_title":"BUZZ-Skye Bioscience与Halozyme合作开发肥胖药物，股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":0.9,"SKYE":0.9},"content_text":"BUZZ-Skye Bioscience rises as it partners with Halozyme on obesity drug** Shares of drug developer Skye Bioscience SKYE.O rise 4.76% to $0.92 premarket** Co says it has signed a global agreement with Halozyme Therapeutics HALO.O to develop and potentially commercialize a new obesity treatment** SKYE says deal will develop injectable version of nimacimab, an experimental obesity drug** Nimacimab aims to help with weight loss; study to test combo with GLP-1 drugs already used for obesity - SKYE** Co plans mid-stage trial of new formulation in mid-2026** Halozyme to get milestone payments and royalties if drug is approved and launched - SKYE** As of last close, stock up ~17% over the past year (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601788664","isCrawlerRequest":true}